Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry.

Autor: Gottlieb AB; Department of Dermatology, Mount Sinai Beth Israel Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alice.gottlieb@mountsinai.org., Merola JF; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Cirulli J; Celgene Corporation, Summit, NJ, USA., Williams CC; Amgen Inc., Thousand Oaks, CA, USA., Linowski GJ; Amgen Inc., Thousand Oaks, CA, USA., Paris M; Amgen Inc., Thousand Oaks, CA, USA., Litman HJ; Corrona, LLC, Waltham, MA, USA., Guo N; Corrona, LLC, Waltham, MA, USA., Emeanuru K; Corrona, LLC, Waltham, MA, USA., McLean RR; Corrona, LLC, Waltham, MA, USA., Cronin A; Corrona, LLC, Waltham, MA, USA., Strober B; Yale University, New Haven, CT, USA.; Central Connecticut Dermatology Research, Cromwell, CT, USA.
Jazyk: angličtina
Zdroj: Dermatology and therapy [Dermatol Ther (Heidelb)] 2021 Feb; Vol. 11 (1), pp. 253-263. Date of Electronic Publication: 2021 Jan 21.
DOI: 10.1007/s13555-020-00479-4
Abstrakt: Introduction: Data on the characteristics of apremilast patients in real-world settings are limited. We assessed the demographics and disease characteristics of apremilast-treated patients in the Corrona Psoriasis Registry overall and by treatment history.
Methods: The Corrona Psoriasis Registry is a large, independent, prospective, observational registry of adult patients (age ≥ 18 years) who initiate an eligible systemic medication for treatment of psoriasis at or after enrollment (incident users) or within 12 months before enrollment (prevalent users). The current analyses included psoriasis patients enrolled in the Corrona Psoriasis Registry between April 1, 2015, and January 7, 2018. Patients were adults (age ≥ 18 years) with psoriasis who were enrolled between April 1, 2015, and January 7, 2018 and initiated apremilast at the time of registry enrollment or a subsequent visit (incident users) or within the 12 months prior to registry enrollment (prevalent users). Patient characteristics were evaluated descriptively at the index date, defined as the enrollment date for prevalent users and the visit when apremilast was initiated for incident users.
Results: Among 660 patients who initiated apremilast at registry enrollment or a visit thereafter, psoriatic arthritis, hypertension, and hyperlipidemia were common. There were more systemic-experienced (61.4%) versus systemic-naive (38.6%) patients; 43.8% had prior biologic exposure. Most patients were not receiving concomitant systemic treatment (70.2%); 27.4% were receiving concomitant biologic therapy. Most patients had mild or moderate disease (psoriasis-involved body surface area ≤ 10% [76.0%], Investigator Global Assessment ≤ 3 [88.3%], Psoriasis Area and Severity Index ≤ 10 [84.5%]). Dermatologist-reported psoriatic arthritis was present in 47.0% of patients; 33.9% of patients had a Psoriasis Epidemiology Screening Tool score  of ≥ 3, suggestive of psoriatic arthritis. Systemic-experienced apremilast patients had higher rates of obesity and comorbidities and experienced a greater impact on quality of life (mean Dermatology Life Quality Index, 7.3 vs. 6.5) versus systemic-naive patients.
Conclusion: In this real-world observational study of apremilast users in the Corrona Psoriasis Registry, most patients had less-severe disease and higher rates of prior exposure to biologic treatments compared with patients with moderate-to-severe psoriasis enrolled in phase 3 clinical studies.
Databáze: MEDLINE
Externí odkaz: